The study highlights the potential of a novel potent, selective and orally available ALK-inhibitor- CH5424802 for treating ALK- rearranged advanced non-small-cell lung cancer (NSCLC).
FIGHT AGAINST CANCER - Cancer is one of the leading causes of mortality now days. The incidence trend indicates that 1 in 3 people on this planet will be affected by cancer . This calls for breakthrough research in areas of therapeutics and biomarkers. Disclosure : The views expressed are that of the author /owner of the blog only.
No comments:
Post a Comment